Huapont Life Sciences Co Ltd
SZSE:002004

Watchlist Manager
Huapont Life Sciences Co Ltd Logo
Huapont Life Sciences Co Ltd
SZSE:002004
Watchlist
Price: 5.41 CNY 3.05% Market Closed
Market Cap: ¥10.7B

EV/OCF

7.4
Current
6%
More Expensive
vs 3-y average of 7

Enterprise Value to Operating Cash Flow (EV/OCF) ratio compares a company`s total enterprise value to its operating cash flow. It shows how much investors are paying for each dollar of the company`s operating cash flow, including both equity and debt.

EV/OCF
7.4
=
Enterprise Value
¥14B
/
Operating Cash Flow
¥1.9B

Enterprise Value to Operating Cash Flow (EV/OCF) ratio compares a company`s total enterprise value to its operating cash flow. It shows how much investors are paying for each dollar of the company`s operating cash flow, including both equity and debt.

EV/OCF
7.4
=
Enterprise Value
¥14B
/
Operating Cash Flow
¥1.9B

Valuation Scenarios

Huapont Life Sciences Co Ltd is trading above its 3-year average

If EV/OCF returns to its 3-Year Average (7), the stock would be worth ¥5.11 (5% downside from current price).

Statistics
Positive Scenarios
3/4
Maximum Downside
-5%
Maximum Upside
+255%
Average Upside
108%
Scenario EV/OCF Value Implied Price Upside/Downside
Current Multiple 7.4 ¥5.41
0%
3-Year Average 7 ¥5.11
-5%
5-Year Average 7.5 ¥5.47
+1%
Industry Average 26.3 ¥19.19
+255%
Country Average 20.8 ¥15.2
+181%

Forward EV/OCF
Today’s price vs future operating cash flow

Not enough data available to calculate forward EV/OCF

Peer Comparison

All Multiples
EV/OCF
P/E
All Countries
Close

Market Distribution

Lower than 82% of companies in China
Percentile
18th
Based on 6 190 companies
18th percentile
7.4
Low
0 — 11.5
Typical Range
11.5 — 39.2
High
39.2 —
Distribution Statistics
China
Min 0
30th Percentile 11.5
Median 20.8
70th Percentile 39.2
Max 266 666.7

Huapont Life Sciences Co Ltd
Glance View

Market Cap
10.7B CNY
Industry
Chemicals

Huapont Life Sciences Co., Ltd., a prominent player in the global pharmaceutical and agrochemical sector, finds its roots in the bustling city of Chongqing, China. Established in 1992, the company swiftly evolved from a regional upstart to a substantial force in the life sciences industry. Huapont's narrative is grounded in its strategic blend of pharmaceutical prowess and agrochemical dexterity. The company's pharmaceutical operations primarily focus on the development, production, and marketing of dermatological and anti-tuberculosis drugs, riding on China's expansive healthcare reforms and increasing demand for specialized medical treatments. This niche approach allows Huapont to capture a substantial share of the market, offering innovative solutions that cater to rising public health concerns. Parallel to its medical endeavors, Huapont has cultivated a robust agrochemical arm. The company leverages advanced research and development to produce and distribute a wide range of crop protection products, including herbicides, fungicides, and insecticides. This diversification in agrochemicals keeps Huapont resilient amidst agricultural cycles and global market fluctuations, providing a steady stream of revenue. By interweaving pharmaceutical advancements with agricultural science, Huapont effectively taps into two essential human needs: health and sustenance. Through these dual pillars, the company harmoniously balances its portfolio, drawing upon scientific research and market insights to drive sustainable growth and enduring value for its stakeholders.

Intrinsic Value
6.35 CNY
Undervaluation 15%
Intrinsic Value
Price ¥5.41
Get AI-powered insights for any company or topic.
Open AI Assistant

Intrinsic Value is all-important and is the only logical way to evaluate the relative attractiveness of investments and businesses.

Warren Buffett